Efficacy of omega-3 for vasomotor symptoms treatment: A randomized controlled trial

Lee S. Cohen, Hadine Joffe, Katherine A. Guthrie, Kristine E. Ensrud, Marlene Freeman, Janet Carpenter, Lee A. Learman, Katherine M. Newton, Susan D. Reed, Joann E. Manson, Barbara Sternfeld, Bette Caan, Ellen W. Freeman, Andrea Z. Lacroix, Lesley F. Tinker, Cathryn Booth-Laforce, Joseph C. Larson, Garnet L. Anderson

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95% CI,-3.0 to-1.9) did not differ significantly from that with placebo (-2.7; 95% CI,-3.3 to-2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI,-0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI,-0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.

Original languageEnglish
Pages (from-to)347-354
Number of pages8
JournalMenopause
Volume21
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Sleep
Randomized Controlled Trials
Placebos
Sleep Initiation and Maintenance Disorders
Capsules
Exercise
Hot Flashes
Yoga
Docosahexaenoic Acids
Omega-3 Fatty Acids
Therapeutics
Anxiety Disorders
Anxiety
Depression
Physicians
Health

Keywords

  • Clinical Trials Network
  • Fish oils
  • Hot flashes
  • Menopause
  • Omega-3
  • Vasomotor symptoms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Cohen, L. S., Joffe, H., Guthrie, K. A., Ensrud, K. E., Freeman, M., Carpenter, J., ... Anderson, G. L. (2014). Efficacy of omega-3 for vasomotor symptoms treatment: A randomized controlled trial. Menopause, 21(4), 347-354. https://doi.org/10.1097/GME.0b013e31829e40b8

Efficacy of omega-3 for vasomotor symptoms treatment : A randomized controlled trial. / Cohen, Lee S.; Joffe, Hadine; Guthrie, Katherine A.; Ensrud, Kristine E.; Freeman, Marlene; Carpenter, Janet; Learman, Lee A.; Newton, Katherine M.; Reed, Susan D.; Manson, Joann E.; Sternfeld, Barbara; Caan, Bette; Freeman, Ellen W.; Lacroix, Andrea Z.; Tinker, Lesley F.; Booth-Laforce, Cathryn; Larson, Joseph C.; Anderson, Garnet L.

In: Menopause, Vol. 21, No. 4, 2014, p. 347-354.

Research output: Contribution to journalArticle

Cohen, LS, Joffe, H, Guthrie, KA, Ensrud, KE, Freeman, M, Carpenter, J, Learman, LA, Newton, KM, Reed, SD, Manson, JE, Sternfeld, B, Caan, B, Freeman, EW, Lacroix, AZ, Tinker, LF, Booth-Laforce, C, Larson, JC & Anderson, GL 2014, 'Efficacy of omega-3 for vasomotor symptoms treatment: A randomized controlled trial', Menopause, vol. 21, no. 4, pp. 347-354. https://doi.org/10.1097/GME.0b013e31829e40b8
Cohen, Lee S. ; Joffe, Hadine ; Guthrie, Katherine A. ; Ensrud, Kristine E. ; Freeman, Marlene ; Carpenter, Janet ; Learman, Lee A. ; Newton, Katherine M. ; Reed, Susan D. ; Manson, Joann E. ; Sternfeld, Barbara ; Caan, Bette ; Freeman, Ellen W. ; Lacroix, Andrea Z. ; Tinker, Lesley F. ; Booth-Laforce, Cathryn ; Larson, Joseph C. ; Anderson, Garnet L. / Efficacy of omega-3 for vasomotor symptoms treatment : A randomized controlled trial. In: Menopause. 2014 ; Vol. 21, No. 4. pp. 347-354.
@article{f73e9a5d10e248a39fe479945d1886b5,
title = "Efficacy of omega-3 for vasomotor symptoms treatment: A randomized controlled trial",
abstract = "OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95{\%} CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95{\%} CI,-3.0 to-1.9) did not differ significantly from that with placebo (-2.7; 95{\%} CI,-3.3 to-2.2), with a relative difference of 0.3 fewer hot flashes per day (95{\%} CI,-0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95{\%} CI,-0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.",
keywords = "Clinical Trials Network, Fish oils, Hot flashes, Menopause, Omega-3, Vasomotor symptoms",
author = "Cohen, {Lee S.} and Hadine Joffe and Guthrie, {Katherine A.} and Ensrud, {Kristine E.} and Marlene Freeman and Janet Carpenter and Learman, {Lee A.} and Newton, {Katherine M.} and Reed, {Susan D.} and Manson, {Joann E.} and Barbara Sternfeld and Bette Caan and Freeman, {Ellen W.} and Lacroix, {Andrea Z.} and Tinker, {Lesley F.} and Cathryn Booth-Laforce and Larson, {Joseph C.} and Anderson, {Garnet L.}",
year = "2014",
doi = "10.1097/GME.0b013e31829e40b8",
language = "English",
volume = "21",
pages = "347--354",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Efficacy of omega-3 for vasomotor symptoms treatment

T2 - A randomized controlled trial

AU - Cohen, Lee S.

AU - Joffe, Hadine

AU - Guthrie, Katherine A.

AU - Ensrud, Kristine E.

AU - Freeman, Marlene

AU - Carpenter, Janet

AU - Learman, Lee A.

AU - Newton, Katherine M.

AU - Reed, Susan D.

AU - Manson, Joann E.

AU - Sternfeld, Barbara

AU - Caan, Bette

AU - Freeman, Ellen W.

AU - Lacroix, Andrea Z.

AU - Tinker, Lesley F.

AU - Booth-Laforce, Cathryn

AU - Larson, Joseph C.

AU - Anderson, Garnet L.

PY - 2014

Y1 - 2014

N2 - OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95% CI,-3.0 to-1.9) did not differ significantly from that with placebo (-2.7; 95% CI,-3.3 to-2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI,-0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI,-0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.

AB - OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95% CI,-3.0 to-1.9) did not differ significantly from that with placebo (-2.7; 95% CI,-3.3 to-2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI,-0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI,-0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.

KW - Clinical Trials Network

KW - Fish oils

KW - Hot flashes

KW - Menopause

KW - Omega-3

KW - Vasomotor symptoms

UR - http://www.scopus.com/inward/record.url?scp=84897413811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897413811&partnerID=8YFLogxK

U2 - 10.1097/GME.0b013e31829e40b8

DO - 10.1097/GME.0b013e31829e40b8

M3 - Article

C2 - 23982113

AN - SCOPUS:84897413811

VL - 21

SP - 347

EP - 354

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 4

ER -